In the recently published ‘Customized Novel Design of 3D Printed Pregabalin Tablets for Instra-Gastric Floating and Controlled Release Using Fused Deposition Modeling,’ Korean researchers examine more detailed use of 3D printing as a vehicle for patient-specific treatment in medications.
While there is attention being paid to the potential for 3D printing of pills, changes within the medical and pharmaceutical industry are still in the beginning stages, following on the heels of FDA approval for Aprecia’s 3D printed epilepsy pill, Spritam. Medication dispensers, and innovations like different shapes and designs of pills for kids have been introduced, but still, there is much to be explored within the realm of fabricating filaments and tablets. In this study, researchers created a new, floating sustained-release system via FDM 3D printing.
Active ingredients for the filaments include:
- Hypromellose acetate succinate (HPMCAS)
- Polyethylene glycol (PEG 400)
Tablets were printed with infill percentages of 25%, 50% and 75%, featuring a bottom layer that is enclosed—but a top layer that is partially open. Filaments and tablets were characterized by:
- Fourier-transform infrared spectroscopy (FTIR)
- Differential scanning calorimetry (DSC)
- X-ray powder diffraction (XRPD)
- Thermogravimetric analysis (TGA)
One of the greatest challenges in the use of pregabalin (approved by the FDA for managing not only epilepsy and diabetes but also other conditions like fibromyalgia and post-herpetic neuralgia) is the half-life of around six hours—meaning that it must be given two to three times a day; however, the researchers have noted that one of the best ways to override the need for more frequent dosing is to increase gastric retention of the medication.
“Floating gastro-retentive formulations can effectively minimize the risk of premature gastric emptying of swellable systems by floating above gastric juice and being away from the pylorus,” state the authors of the study. “Previously, an intragastric floating tablets of domperidone was formulated using 3D technology. As FDM 3D technology requires filaments as the main material, hydroxy-propyl cellulose filaments loaded with domperidone were prepared using hot melt extruder and hollow tablets were made using a 3D printer. Printed tablets were studied for in vitro and in vivo floating time and drug release profile, which demonstrated a promising application of FDM technology to reduce the frequency of administration and improve patient compliance.”
While tapping into previous research and combining information, the researchers created their own system featuring pregabalin in a floating tablet. Drug delivery is under controlled release. During the study, the researchers discovered that diameter uniformity affected weight variations. A partial crystalline structure was observed, also, during extrusion, with an endothermic peak of pure pregabalin at 194.81 °C. The team also noted a two to three percent mass loss in the hot melt extrudable (HME) zone, with only five percent in the printing zone. They attribute this to the possibility of high temperatures and degradation of material.
While previous research has found floating capacity and resulting duration to revolve around density of tablets, here, the researchers found a direct connection between the existence of both a top and bottom layer—and minimum dependency of density.
“To understand the release properties better, drug release data were fitted to different mathematical kinetic models,” explained the researchers in conclusion. “A single model could not define the drug release pattern from tablets and rather seemed to have a combination of different mechanisms. The regression value was found to be higher for the Zero-order and Higuchi models, suggesting that the release and diffusion rates were constant. Drug release for HPMCAS polymers have been found to be regulated by the drug diffusion and erosion polymer from the surface of the system. Printed tablets did not show any changes in morphology and maintained their integrity during whole dissolution process.
“The results show that FDM printing is suitable for the formulation of floating dosage form with the desired drug release profile.”
What do you think of this news? Let us know your thoughts; join the discussion of this and other 3D printing topics at 3DPrintBoard.com.[Source / Images: ‘Customized Novel Design of 3D Printed Pregabalin Tablets for Instra-Gastric Floating and Controlled Release Using Fused Deposition Modeling’]
Subscribe to Our Email Newsletter
Stay up-to-date on all the latest news from the 3D printing industry and receive information and offers from third party vendors.
You May Also Like
Twikit to Bring 3D Printing Personalization to Oqton’s Manufacturing OS
While Oqton is working to fully weave a digital thread through the world of manufacturing, Twikit has made strides in design automation to introduce personalization platform to 3D printing. Now,...
What if 3D Printing Mass Customized Everything at the Voxel Level?
When we think of mass customization and 3D printing, we often think of personalizing an object’s shape. Shape alone, however, doesn’t often make a good business case. Frequently, additive manufacturing...
3D Printing News Unpeeled: Impossible Objects, Soft Tissue Bitmaps and Aerorise
Weber University’s Miller Advanced Research and Solutions Center (MARS Center) has bought an Impossible Objects Composite-Based Additive Manufacturing system the CBAM-2. It is now reportedly using the system to make upgrades to...
Mass Customization: Proof that Complexity Isn’t Free – AMS Speaker Spotlight
Mass customization is a manufacturing paradigm where custom products are produced at large volumes that are traditionally only achievable by conventional mass production. Additive manufacturing (AM), or 3D printing, has...
Upload your 3D Models and get them printed quickly and efficiently.